Synthesis of benzamide derivatives as TRPV1 antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 3, 2008, Pages 1072-1078

  Shishido, Yuji ^a   Jinno, Madoka ^a   Ikeda, Takafumi ^a   Ito, Fumitaka ^a   Sudo, Masaki ^a   Makita, Naoya ^a   Ohta, Atsuko ^a   Iki Taki, Ayako ^a   Ohmi, Takashi ^a   Kanai, Yoshihito ^a   Tamura, Tetsuya ^a   Shimojo, Masato ^a  

^a PFIZER INC   (United States)

Author keywords

Antagonist; Bioisostere; Tetrahydrocarbazole; TRPV1; Vanilloid

Indexed keywords

BENZAMIDE DERIVATIVE; CALCIUM; CAPSAICIN; INDOLE; NAPHTHYL GROUP; RECEPTOR BLOCKING AGENT; TRYPTAMINE; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1 BLOCKING AGENT;

ANIMAL EXPERIMENT; ARTICLE; CALCIUM TRANSPORT; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG SYNTHESIS; EMBRYO; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC 50; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ANALGESICS; ANIMALS; BENZAMIDES; COMBINATORIAL CHEMISTRY TECHNIQUES; HUMANS; MICE; MOLECULAR STRUCTURE; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; TRPV CATION CHANNELS;

EID: 38749092213     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.12.007     Document Type: Article

References (21)

1. Szallasi A., and Blumberg P.M. Pharmacol. Rev. 51 (1999) 159
2. For recent reviews on vanilloids, see. Szallasi A., Cortright D.N., Blum C.A., and Eid S.R. Nat. Rev. Drug Discov. 6 (2007) 357
3. Szallasi A., and Appendino G. J. Med. Chem. 47 (2004) 2717
4. Roberts, L. A.; Conner, M. Recent Patents CNS Drug Discov. 2006, 1, 65.
5. Caterina M.J. Pain 105 (2003) 5
6. McGaraughty S., Chu K.L., Bitner R.S., Martino B., El Kouhen R., Han P., Nikkel A.L., Burgard E.C., Faltynek C.R., and Jarvis M.F. J. Neurophysiol. 90 (2003) 2702
7. Tominaga M., Caterina M., Malmgerg A., Rosen T., Gilbert H., Skinner K., Raumann B., Basbaum A., and Julius D. Neuron 21 (1998) 531
8. Caterina M.J., Schumacher M.A., Tominaga M., Rosen T.A., Levine J.D., and Julius D. Nature 389 (1997) 816
9. Caterina M.J., Leffler A., Malmberg A.B., Martin W.J., Trafton J., Petesen-Zeiet K.R., Basbaum A.I., and Julius D. Science 288 (2000) 306
10. Davis J.B., Gray J., Gunthope M.J., Hatcher J.P., Davey P.T., Overend P., Harries M.H., Latcham J., Claphams C., Atkinson K., Hughes S.A., Rance K., Grau E., Harper A.J., Pugh P.L., Rogers D.C., Bingham S., Randall A., and Sheardown S.A. Nature 405 (2000) 183
11. Nakao, K.; Nagayama, S.; Shishido, Y.; Hirano, M.; Sudo, M.; Takada, J.; Kanai, Y. Abstracts of Papers, 232th ACS National Meeting, San Francisco, CA, United States, September 10-14, 2006.
12. 2+ entry followed by the activation of intrinsic muscarinic receptors expressed on HEK-293 cells.
13. N-(4-tert-Butylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2H)-carboxamide (BCTC). Valenzano K.J., Grant E.R., Wu G., Hachicha M., Schmid L., Tafesse L., Sun Q., Rotshteyn Y., Francis J., Limberis J., Malik S., Whittemore E.R., and Hodges D. J. Pharmacol. Exp. Ther. 306 (2003) 377
14. Sun Q., Tafesse L., Islam K., Zhou X., Victory S.F., Zhang C., Hachicha M., Schmid L., Patel A., Rotshteyn Y., Valenzano K.J., and Kyle D.J. Bioorg. Med. Chem. Lett. 13 (2003) 3611
15. In this assay, we confirmed that compound 4 did not convert to TRPV1 agonist metabolites after systemic administration by monitoring the rectal temperature of the mice/rats.
16. Shao B., Huang J., Sun Q., Valenzano K.J., Schmid L., and Nolan S. Bioorg. Med. Chem. Lett. 15 (2005) 719
17. Fletcher S.R., McIver E., Lewis S., Burkamp F., Leech C., Mason G., Boyce S., Morrison D., Richards G., Sutton K., and Jones A.B. Bioorg. Med. Chem. Lett. 16 (2006) 2872
18. Szallasi A., Cortright D.N., Blum C.A., and Eid S.R. Nat. Rev. Drug Discov. 6 (2007) 357
19. Bevan S., Hothi S., Hughes G., James I.F., Rang H.P., Shah K., Walpole C.S., and Yeats J.C. Br. J. Pharmacol 107 (1992) 544
20. Steinhilber D., and Carlberg C. Exp. Opin. Ther. Patents 9 (1999) 281
21. Davies D.J., Garratt P.J., Tocher D.A., and Vonhoff S. J. Med. Chem. 41 (1998) 451